Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teriparatide followed by zoledronic acid for adults with osteogenesis imperfecta
NL-OMON55540Phase 4Recruiting
- Sponsor
- Accord Healthcare
- Start
- Jan 2022
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of teriparatide and zoledronic acid in osteogenesis imperfecta (OI) (2 arms), sponsored by Accord Healthcare. Primary endpoint: Fractures validated by imaging. Started Jan 2022; status: recruiting.
02
Drugs
teriparatidezoledronic acid
03
Conditions
osteogenesis imperfecta (OI)
Beyond the preview
Go deeper on NL-OMON55540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55540.